{"id":"trospium-cl","safety":{"commonSideEffects":[{"rate":"20-30","effect":"Dry mouth"},{"rate":"10-20","effect":"Constipation"},{"rate":"5-10","effect":"Headache"},{"rate":"5-10","effect":"Dizziness"},{"rate":"5","effect":"Blurred vision"}]},"_chembl":{"chemblId":"CHEMBL1888176","moleculeType":"Small molecule","molecularWeight":"392.52"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Trospium chloride competitively antagonizes muscarinic acetylcholine receptors on detrusor smooth muscle in the bladder. By blocking these receptors, it decreases the frequency and amplitude of bladder contractions, thereby reducing symptoms of overactive bladder such as urgency, frequency, and urge incontinence. As a quaternary ammonium compound, it has limited blood-brain barrier penetration, which may reduce central nervous system side effects compared to tertiary amine anticholinergics.","oneSentence":"Trospium chloride is an anticholinergic agent that blocks muscarinic receptors in the bladder smooth muscle, reducing involuntary contractions and urinary urgency.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:14:50.162Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Overactive bladder with symptoms of urge incontinence, urgency, and frequency"}]},"trialDetails":[{"nctId":"NCT06126224","phase":"PHASE3","title":"A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-2)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Karuna Therapeutics, Inc., a Bristol Myers Squibb company","startDate":"2023-08-28","conditions":"Psychosis Associated With Alzheimer's Disease","enrollment":500},{"nctId":"NCT07011732","phase":"PHASE3","title":"A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1)","status":"RECRUITING","sponsor":"Bristol-Myers Squibb","startDate":"2025-07-10","conditions":"Alzheimer Disease","enrollment":352},{"nctId":"NCT05980949","phase":"PHASE3","title":"Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)","status":"RECRUITING","sponsor":"Karuna Therapeutics, Inc., a Bristol Myers Squibb company","startDate":"2023-07-11","conditions":"Psychosis Associated With Alzheimer's Disease","enrollment":800},{"nctId":"NCT05511363","phase":"PHASE3","title":"A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-1)","status":"RECRUITING","sponsor":"Karuna Therapeutics, Inc., a Bristol Myers Squibb company","startDate":"2022-08-23","conditions":"Psychosis Associated With Alzheimer's Disease","enrollment":410},{"nctId":"NCT06951711","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-2)","status":"RECRUITING","sponsor":"Bristol-Myers Squibb","startDate":"2025-06-13","conditions":"Bipolar Disorder Type I With Mania or Mania With Mixed Features","enrollment":274},{"nctId":"NCT06929273","phase":"PHASE3","title":"A Study to Assess the Long-term Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-3)","status":"RECRUITING","sponsor":"Bristol-Myers Squibb","startDate":"2025-07-18","conditions":"Bipolar Disorder Type I With Mania","enrollment":450},{"nctId":"NCT06951698","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder","status":"RECRUITING","sponsor":"Bristol-Myers Squibb","startDate":"2025-06-11","conditions":"Bipolar-I Disorder With Mania or Mania With Mixed Features","enrollment":274},{"nctId":"NCT06937229","phase":"PHASE3","title":"A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)","status":"RECRUITING","sponsor":"Bristol-Myers Squibb","startDate":"2025-12-02","conditions":"Alzheimer Disease, Agitation","enrollment":600},{"nctId":"NCT07101094","phase":"","title":"Evaluation of Treatment Satisfaction and KarXT Utilization Registry (RESKU)","status":"RECRUITING","sponsor":"Bristol-Myers Squibb","startDate":"2025-09-22","conditions":"Schizophrenia","enrollment":300},{"nctId":"NCT05304767","phase":"PHASE3","title":"An Extension Study to Assess Long-Term Safety and Tolerability of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of Schizophrenia","status":"RECRUITING","sponsor":"Karuna Therapeutics, Inc., a Bristol Myers Squibb company","startDate":"2022-03-07","conditions":"Schizophrenia","enrollment":280},{"nctId":"NCT07221877","phase":"PHASE4","title":"A Study to Evaluate the Effect of KarXT on Urological Safety","status":"RECRUITING","sponsor":"Bristol-Myers Squibb","startDate":"2026-01-20","conditions":"Schizophrenia","enrollment":60},{"nctId":"NCT07379827","phase":"","title":"Effectiveness and Adverse-effect Switch Evaluation of Xanomeline and Trospium Chloride (KarXT)","status":"RECRUITING","sponsor":"Bristol-Myers Squibb","startDate":"2026-02-26","conditions":"Schizophrenia","enrollment":1500},{"nctId":"NCT07011745","phase":"PHASE3","title":"A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-2)","status":"RECRUITING","sponsor":"Bristol-Myers Squibb","startDate":"2025-07-16","conditions":"Alzheimer Disease","enrollment":352},{"nctId":"NCT07084831","phase":"PHASE3","title":"A Study Evaluating the Efficacy of Xanomeline/Trospium (XT) on Cognitive Impairment After 24 and 52 Weeks of Treatment in Adult Participants With Schizophrenia","status":"RECRUITING","sponsor":"European Group for Research In Schizophrenia","startDate":"2026-01-14","conditions":"Schizophrenia; Psychosis, Cognitive Impairment","enrollment":171},{"nctId":"NCT07118215","phase":"PHASE1","title":"A Study to Evaluate the Effects of KarXT on the Drug Levels of Midazolam, Fexofenadine, and Digoxin","status":"RECRUITING","sponsor":"Karuna Therapeutics, Inc., a Bristol Myers Squibb company","startDate":"2025-09-29","conditions":"Healthy Volunteers","enrollment":60},{"nctId":"NCT06729970","phase":"PHASE1","title":"A Study to Evaluate the Effects of Lithium, Valproic Acid, and Lamotrigine on the Pharmacokinetics of KarXT and Effects of KarXT on the Pharmacokinetics of Lithium, Valproic Acid, and Lamotrigine in Healthy Participants","status":"COMPLETED","sponsor":"Karuna Therapeutics, Inc., a Bristol Myers Squibb company","startDate":"2024-12-26","conditions":"Healthy Volunteers","enrollment":133},{"nctId":"NCT07140913","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Adjunctive KarXT for the Treatment of Mania, With or Without Mixed Features, in Participants With Bipolar-I Disorder Taking Lithium, Valproate, or Lamotrigine","status":"RECRUITING","sponsor":"Bristol-Myers Squibb","startDate":"2025-10-08","conditions":"Mania, Bipolar Disorder","enrollment":424},{"nctId":"NCT07423546","phase":"PHASE1, PHASE2","title":"A PET/MRI Study of Cobenfy on Dopamine Transmission in Schizophrenia","status":"NOT_YET_RECRUITING","sponsor":"New York State Psychiatric Institute","startDate":"2026-04-01","conditions":"SCHIZOPHRENIA 1 (Disorder), Schizoaffecitve Disorder","enrollment":12},{"nctId":"NCT07204418","phase":"PHASE1","title":"A Study to Evaluate the Effects of CYP2D6 Phenotypes on the Pharmacokinetics of Xanomeline Following KarXT Administration in Healthy Adult Participants","status":"RECRUITING","sponsor":"Karuna Therapeutics, Inc., a Bristol Myers Squibb company","startDate":"2025-10-13","conditions":"Healthy Volunteers","enrollment":56},{"nctId":"NCT07257120","phase":"PHASE4","title":"KarXT Concentrations in the Breast Milk and Plasma of Lactating Females","status":"RECRUITING","sponsor":"Karuna Therapeutics, Inc., a Bristol Myers Squibb company","startDate":"2026-01-09","conditions":"Healthy Volunteers","enrollment":8},{"nctId":"NCT07284745","phase":"PHASE3","title":"A Study of KarXT + KarX-EC for Treatment of Irritability in Children and Adolescents With Autism","status":"NOT_YET_RECRUITING","sponsor":"Bristol-Myers Squibb","startDate":"2026-02-27","conditions":"Irritability Associated With Autism Spectrum Disorder","enrollment":176},{"nctId":"NCT07285798","phase":"PHASE3","title":"A Study of KarXT + KarX-EC for Treatment of Irritability in Children and Adolescents With Autism Spectrum Disorder","status":"NOT_YET_RECRUITING","sponsor":"Bristol-Myers Squibb","startDate":"2026-02-27","conditions":"Irritability Associated With Autism Spectrum Disorder","enrollment":176},{"nctId":"NCT07063342","phase":"PHASE1","title":"A Study to Evaluate Novel KarX and KarT Prototypes Versus the KarXT and KarX-EC Reference Following Single Doses, and to Explore the Effect of Food After Multiple Doses of Selected Prototypes in Healthy Adult Participants","status":"RECRUITING","sponsor":"Bristol-Myers Squibb","startDate":"2025-06-27","conditions":"Healthy Volunteers","enrollment":72},{"nctId":"NCT05919823","phase":"PHASE3","title":"A Study to Assess the Efficacy and Safety of KarXT in Acutely Psychotic Hospitalized Chinese Adult Subjects With DSM-5 Schizophrenia","status":"COMPLETED","sponsor":"Karuna Therapeutics, Inc., a Bristol Myers Squibb company","startDate":"2023-05-29","conditions":"Schizophrenia","enrollment":202},{"nctId":"NCT05880862","phase":"EARLY_PHASE1","title":"Comparative Effectiveness of Initial OAB Treatment Options Among Older Women at High Risk of Falls","status":"ACTIVE_NOT_RECRUITING","sponsor":"The University of Texas Medical Branch, Galveston","startDate":"2023-09-28","conditions":"Urinary Bladder, Overactive, Urinary Incontinence, Accidental Falls","enrollment":48},{"nctId":"NCT04227184","phase":"PHASE4","title":"Investigation of Brain Mechanisms Involved in Urgency Urinary Incontinence","status":"COMPLETED","sponsor":"Becky Clarkson","startDate":"2020-02-13","conditions":"Urgency Urinary Incontinence","enrollment":207},{"nctId":"NCT07212062","phase":"PHASE2","title":"The Purpose of This Study is to Evaluate the Safety and Tolerability of X/T+X-EC in Participants With Alzheimer's Disease Who Are Currently Treated With Lecanemab.","status":"NOT_YET_RECRUITING","sponsor":"Neurology Office of South Florida","startDate":"2025-12-01","conditions":"Alzheimers Disease","enrollment":60},{"nctId":"NCT04820309","phase":"PHASE3","title":"An Open-label Study to Assess the Long-term Safety, Tolerability, and Efficacy of KarXT in Adult Patients With Schizophrenia (EMERGENT-5)","status":"COMPLETED","sponsor":"Karuna Therapeutics, Inc., a Bristol Myers Squibb company","startDate":"2021-06-02","conditions":"Schizophrenia","enrollment":566},{"nctId":"NCT06853171","phase":"PHASE1","title":"Safety, Tolerability, and Pharmacokinetics of KarXT and Dual-burst Release of Xanomeline With Immediate-release Trospium Chloride in Adolescents With Psychiatric Disorders","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2025-04-29","conditions":"Psychiatric Disorders","enrollment":24},{"nctId":"NCT06346522","phase":"PHASE4","title":"Gabapentin Versus Trospium Chloride for Prevention of a Catheter-related Bladder Discomfort Inside the ICU","status":"COMPLETED","sponsor":"Ain Shams University","startDate":"2024-04-10","conditions":"Catheter-related Bladder Discomfort (CRBD)","enrollment":120},{"nctId":"NCT06605950","phase":"PHASE1","title":"A Study to Assess the Safety, Tolerability and Pharmacokinetics (PK) of Xanomeline With Trospium Chloride Versus KarXT in Healthy Adult and Elderly Participants of Japanese Ethnicity and to Assess the Effect of Omeprazole on the PK of Xanomeline With Trospium Chloride in Healthy Adult Participants","status":"COMPLETED","sponsor":"Karuna Therapeutics, Inc., a Bristol Myers Squibb company","startDate":"2024-10-01","conditions":"Healthy Volunteers","enrollment":78},{"nctId":"NCT06947941","phase":"PHASE3","title":"A Study to Evaluate Safety and Efficacy of KarXT + KarX-EC as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-5)","status":"NOT_YET_RECRUITING","sponsor":"Bristol-Myers Squibb","startDate":"2025-07-31","conditions":"Alzheimer Disease, Psychosis","enrollment":1046},{"nctId":"NCT06923891","phase":"PHASE4","title":"An Open-Label Study to Evaluate the Efficacy and Tolerability of Xanomeline/Trospium In First Episode/Early Phase Schizophrenia Patients","status":"NOT_YET_RECRUITING","sponsor":"Vanguard Research Group","startDate":"2025-04-16","conditions":"Schizophrenia","enrollment":172},{"nctId":"NCT06924255","phase":"PHASE4","title":"An 8-week Open-label Study of an Accelerated and Slower Switching to Xanomeline/Trospium Following Atypical Antipsychotic Treatment in Participants With Schizophrenia","status":"NOT_YET_RECRUITING","sponsor":"Collaborative Neuroscience Research, LLC","startDate":"2025-04","conditions":"Schizophrenia Disorders","enrollment":100},{"nctId":"NCT05145413","phase":"PHASE3","title":"A Study to Assess Efficacy and Safety of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of Schizophrenia","status":"COMPLETED","sponsor":"Karuna Therapeutics, Inc., a Bristol Myers Squibb company","startDate":"2021-11-12","conditions":"Schizophrenia","enrollment":396},{"nctId":"NCT04738123","phase":"PHASE3","title":"A Study to Assess Efficacy and Safety of KarXT in Acutely Psychotic Hospitalized Adult Patients With Schizophrenia (EMERGENT-3)","status":"COMPLETED","sponsor":"Karuna Therapeutics, Inc., a Bristol Myers Squibb company","startDate":"2021-04-06","conditions":"Schizophrenia, Schizophrenia; Psychosis","enrollment":256},{"nctId":"NCT04659174","phase":"PHASE3","title":"An Extension Study to Assess Long-term Safety, Tolerability, and Efficacy of KarXT in Adult Patients With Schizophrenia (EMERGENT-4)","status":"COMPLETED","sponsor":"Karuna Therapeutics, Inc., a Bristol Myers Squibb company","startDate":"2021-02-01","conditions":"Schizophrenia","enrollment":152},{"nctId":"NCT03602508","phase":"","title":"Treatment Persistence Among Patients With Overactive Bladder: A Retrospective Secondary Data Analysis in Asia Oceania","status":"COMPLETED","sponsor":"Astellas Pharma Singapore Pte. Ltd.","startDate":"2018-07-20","conditions":"Overactive Bladder (OAB)","enrollment":5589},{"nctId":"NCT02386072","phase":"","title":"A Prospective, Observational, Multicenter Study of Patients Following Initiation of a New Course of Treatment for Overactive Bladder (OAB)","status":"COMPLETED","sponsor":"Astellas Scientific & Medical Affairs, Inc.","startDate":"2015-01-05","conditions":"Urinary Bladder Overactive, Overactive Bladder, Urinary Bladder Diseases","enrollment":1524},{"nctId":"NCT05643170","phase":"PHASE3","title":"An Open-label Study to Assess the Long-term Safety, Tolerability, Effectiveness, and Durability of Effect of KarXT in Patients With DSM-5 Diagnosis of Schizophrenia","status":"TERMINATED","sponsor":"Karuna Therapeutics, Inc., a Bristol Myers Squibb company","startDate":"2022-11-08","conditions":"Schizophrenia","enrollment":4},{"nctId":"NCT04659161","phase":"PHASE3","title":"A Study to Assess Efficacy and Safety of KarXT in Acutely Psychotic Hospitalized Adult Patients With Schizophrenia (EMERGENT-2)","status":"COMPLETED","sponsor":"Karuna Therapeutics, Inc., a Bristol Myers Squibb company","startDate":"2020-12-16","conditions":"Schizophrenia, Schizophrenia; Psychosis","enrollment":252},{"nctId":"NCT03709992","phase":"NA","title":"Trospium Chloride vs Tamsulosin in Treatment of Ureteral Stent Related Symptoms:","status":"SUSPENDED","sponsor":"Mansoura University","startDate":"2020-12-18","conditions":"Ureter Stone, Quality of Life, Ureter Obstruction","enrollment":200},{"nctId":"NCT04090190","phase":"PHASE4","title":"Inflammation in Women With Urgency Urinary Incontinence Treated With Anticholinergics","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2019-10-30","conditions":"Urinary Incontinence, Urgency Urinary","enrollment":20},{"nctId":"NCT03697252","phase":"PHASE2","title":"A Study to Assess Safety and Efficacy of KarXT in Adult Patients With Schizophrenia","status":"COMPLETED","sponsor":"Karuna Therapeutics, Inc., a Bristol Myers Squibb company","startDate":"2018-09-18","conditions":"Schizophrenia","enrollment":182},{"nctId":"NCT03572231","phase":"","title":"A Registry Study of Patients Initiating a Course of Drug Therapy for Overactive Bladder in Taiwan, Korea and China","status":"COMPLETED","sponsor":"Astellas Pharma Singapore Pte. Ltd.","startDate":"2018-07-19","conditions":"Overactive Bladder (OAB)","enrollment":805},{"nctId":"NCT01499069","phase":"NA","title":"Urinary Nerve Growth Factor (NGF), Prostaglandin E2 (PGE2)and Adenosine Triphosphate (ATP): Potential Biomarkers in Overactive Bladder Patients","status":"COMPLETED","sponsor":"Samsung Medical Center","startDate":"2010-02","conditions":"Overactive Bladder","enrollment":191},{"nctId":"NCT01166438","phase":"PHASE3","title":"Anticholinergic vs. Botox Comparison Study","status":"COMPLETED","sponsor":"NICHD Pelvic Floor Disorders Network","startDate":"2010-03","conditions":"Urge Urinary Incontinence, Overactive Bladder","enrollment":249},{"nctId":"NCT02831231","phase":"PHASE1","title":"Pilot Study Comparing Effects of Xanomeline Alone to Xanomeline Plus Trospium","status":"COMPLETED","sponsor":"Karuna Therapeutics, Inc., a Bristol Myers Squibb company","startDate":"2016-09-07","conditions":"Schizophrenia","enrollment":70},{"nctId":"NCT03011463","phase":"PHASE1","title":"Pharmacokinetic Interaction Between Trospium With an Inhibitor of OCT1 and of P-gp in Subjects Genotyped for OCT1","status":"COMPLETED","sponsor":"Dr. R. Pfleger Chemische Fabrik GmbH","startDate":"2016-11","conditions":"Pharmacokinetics, Inhibition Enzyme, Drug Interaction Potentiation","enrollment":24},{"nctId":"NCT03104101","phase":"NA","title":"Transcutaneous Posterior Tibial Nerve Electrostimulation With Low Dose Trospium Chloride in OAB in Females","status":"COMPLETED","sponsor":"Alexandria University","startDate":"2014-11-01","conditions":"Overactive Bladder","enrollment":30},{"nctId":"NCT01922115","phase":"PHASE4","title":"The Effect of Anticholinergics on Cognitive Function in the Elderly","status":"COMPLETED","sponsor":"University of North Carolina, Chapel Hill","startDate":"2013-06","conditions":"Mental Competency, Urinary Bladder, Overactive, Cognitive Function","enrollment":59},{"nctId":"NCT01178827","phase":"PHASE4","title":"Sanctura Muscarinic Receptor Antagonist Resists Transport (SMART-II) Trial","status":"COMPLETED","sponsor":"Allergan","startDate":"2010-08","conditions":"Overactive Bladder","enrollment":20},{"nctId":"NCT00863551","phase":"PHASE4","title":"Sanctura Muscarinic Receptor Antagonist Resists Transport (SMART) Trial","status":"COMPLETED","sponsor":"Allergan","startDate":"2009-04","conditions":"Elderly, Pharmacokinetics, Overactive Bladder","enrollment":12},{"nctId":"NCT00465959","phase":"PHASE1, PHASE2","title":"Study of Trospium Chloride Inhalation Powder (TrIP) in Patients With Chronic Obstructive Pulmonary Disease","status":"COMPLETED","sponsor":"Endo Pharmaceuticals","startDate":"2007-04","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":24},{"nctId":"NCT01089751","phase":"PHASE4","title":"Efficacy of Sanctura XR (Trospium Chloride) for Reducing Overactive Bladder Symptoms in Female Subjects Refractory to Detrol LA (Tolterodine Tartrate Extended Release) Daily","status":"COMPLETED","sponsor":"Allergan","startDate":"2010-03","conditions":"Overactive Bladder","enrollment":322},{"nctId":"NCT00800462","phase":"PHASE4","title":"Comparative Study of the Efficacy and Safety of Muscarinic M3 Receptors Antagonists in the Treatment of Neurogenic Detrusor Overactivity","status":"COMPLETED","sponsor":"Toronto Rehabilitation Institute","startDate":"2008-03","conditions":"Spinal Cord Injury, Neurogenic Detrusor Overactivity","enrollment":23},{"nctId":"NCT00932022","phase":"PHASE4","title":"Trospium Chloride XR in Obese Female Patients With Overactive Bladder","status":"COMPLETED","sponsor":"Allergan","startDate":"2009-07","conditions":"Obesity, Overactive Bladder, Incontinence","enrollment":127},{"nctId":"NCT00986401","phase":"PHASE1","title":"Safety and Tolerability of Trospium Chloride and Metformin Hydrochloride in Healthy Subjects","status":"COMPLETED","sponsor":"Allergan","startDate":"2009-10","conditions":"Healthy","enrollment":44},{"nctId":"NCT00801684","phase":"PHASE2","title":"ALK27-001: A Study of Trospium Inhalation Powder (TrIP)Administered to Subjects With COPD","status":"COMPLETED","sponsor":"Alkermes, Inc.","startDate":"2009-02","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":24}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Trosec"],"phase":"marketed","status":"active","brandName":"Trospium Cl","genericName":"Trospium Cl","companyName":"Toronto Rehabilitation Institute","companyId":"toronto-rehabilitation-institute","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Trospium chloride is an anticholinergic agent that blocks muscarinic receptors in the bladder smooth muscle, reducing involuntary contractions and urinary urgency. Used for Overactive bladder with symptoms of urge incontinence, urgency, and frequency.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}